Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Basit Öğe Kaydı
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorÇakan Demirel, Burçin
dc.contributor.authorBilici, Ahmet
dc.contributor.authorTopçu, Atakan
dc.contributor.authorAykan, Musa Barış
dc.contributor.authorKahraman, Seda
dc.contributor.authorAkbıyık, Ilgın
dc.contributor.authorAtçı, Muhammed Mustafa
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorYaren, Arzu
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorGeredeli, Çağlayan
dc.contributor.authorŞeker, Mesut
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorAydın, Ahmet
dc.date.accessioned2022-12-01T10:49:49Z
dc.date.available2022-12-01T10:49:49Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractObjectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to investigate the role of systemic inflammatory parameters (SIP) and other possible independent factors that may affect survival and treatment approaches and to determine the benefit of later-line treatments in these patients. Methods: A total of 284 patients, initially diagnosed with advanced stage or progressed after curative treatment of BTC, from different oncology centers in Turkey were included in this retrospective study. The prognostic significance of clinicopathological factors, SIPs and treatment options was analyzed. Results: At a median follow-up of 13 months, the median progression-free survival (PFS) was 6.1 months (95% CI:5.51–6.82), and the median overall survival (OS) time was 16.8 months (95% CI: 13.9–19.6). Treatment choice (p <.001 HR:0.70 CI95% 0.55–0.9), performance status (p <.001 HR:2.74 CI 95% 2.12–3.54) and neutrophil-to-lymphocyte ratio (NLR) (p =.02 HR:1.38 CI 95% 1.03–1.84) were independent prognostic factors for PFS. For OS, the independent prognostic indicators were determined as The Eastern Cooperative Oncology Group Performance Status (ECOG PS) (p <.001 HR:1.78 CI 95% 1.5–2.3), Systemic Immune-inflammation Index (SII) (p <.001 HR:0.51 CI95% 0.36–0.73) and stage at diagnosis (p =.002 HR:1.79 CI 95% 1.24–2.59). Furthermore, second and third line treatments significantly prolonged OS in advanced BTC (p <.001 HR:0.55 CI 95% 0.38–0.79; p =.007 HR:0.51 CI95% 0.31–0.83, respectively). Conclusion: SII and NLR are useful prognostic factors and may be helpful in making treatment decisions. Additionally, second and later-line treatments in advanced BTC have a significant impact on survival under real-life conditions.
dc.identifier.citationGöktaş Aydın, S., Çakan Demirel, B., Bilici, A., Topçu, A., Aykan, M. B., Kahraman, S. ... Aydın, A. (2022). Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer. Current Medical Research and Opinion, 38(10), 1751-1758. https://doi.org/10.1080/03007995.2022.2108619
dc.identifier.doi10.1080/03007995.2022.2108619
dc.identifier.endpage1758
dc.identifier.issn0300-7995
dc.identifier.issn1473-4877
dc.identifier.issue10
dc.identifier.pmid35916475
dc.identifier.scopus2-s2.0-85136162860
dc.identifier.scopusqualityQ2
dc.identifier.startpage1751
dc.identifier.urihttps://doi.org/10.1080/03007995.2022.2108619
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10057
dc.identifier.volume38
dc.identifier.wos000841144000001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofCurrent Medical Research and Opinionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectBiliary Tract Cancer
dc.subjectNLR
dc.subjectSII
dc.subjectSecond-Line Chemotherapy
dc.subjectBest Supportive Care
dc.titleReal-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydin-Sabin-2022.pdf
Boyut:
1.63 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu